Experimental HIV vaccine passes early safety test in healthy volunteers
NCT ID NCT03220724
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental HIV vaccine in 117 healthy, HIV-negative adults to see if it is safe and triggers an immune response. Participants received several injections of the vaccine or a placebo. The main goals were to check for side effects and measure antibody levels. Results will guide future HIV vaccine research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Experimental HIV vaccine (EnvSeq-1 and CH505 M5 gp120 proteins with GLA-SE adjuvant)
What this could lead to
If successful, this could help develop a vaccine to prevent HIV infection.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The vaccine may not produce strong enough immunity to prevent HIV, and further studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35294, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032-3732, United States
-
New York Blood Center CRS
New York, New York, 10065, United States
-
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98104, United States
-
University of Rochester Vaccines to Prevent HIV Infection CRS
Rochester, New York, 14642, United States